MUC1 and neoplasm: The most clinically advancedarea in mRNA-based cancer therapy is vaccination employing tumor-associatedor tumor-specific antigens (Figure a). Protamine-formulatedCV9201 is an mRNA vaccine that encodes five shared NSCLC antigens,and its later version CV9202 (BI 1361849) includes the same five sequencesplus a sixth, Mucin 1, within a single transcript.